Bladder Cancer
Risk Factors Involved in the High Incidence of Bladder Cancer in an Industrialized Area in North-Eastern Spain: A Case-Control Study.
January 27, 2023
Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections.
January 26, 2023
Long-Term Outcome of Patients with Stage II and III Muscle-Invasive Urothelial Bladder Cancer after Multimodality Approach. Which Is the Best Option?
January 25, 2023
Transcriptomic Changes Associated with IFN-Gamma Treatment in Bladder Cancer - Expert Commentary
January 24, 2023
Diagnosis, treatment and survival from bladder, upper urinary tract and urethral cancers: Real world findings from NHS England between 2013 and 2019.
January 24, 2023
Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum.
January 24, 2023
Contemporary Systemic Therapies in Urothelial Carcinoma.
January 24, 2023
The Urothelial Transcriptomic Response to Interferon Gamma: Implications for Bladder Cancer Prognosis and Immunotherapy.
January 24, 2023
Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients.
January 23, 2023
Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy.
January 23, 2023
Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.
January 20, 2023
Neoadjuvant Gemcitabine-Carboplatin Versus Gemcitabine-Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Expert Commentary
January 19, 2023